TTNP Titan Pharmaceuticals Inc.

1.46
-0.07  -5%
Previous Close 1.53
Open 1.53
Price To Book 3.48
Market Cap 527051
Shares 360,994
Volume 240,619
Short Ratio
Av. Daily Volume 887,109

SEC filingsSee all SEC filings

  1. 8-K - Current report 19600406
  2. 8-K - Current report 19540803
  3. DEF 14A - Other definitive proxy statements 181244461
  4. PRE 14A - Other preliminary proxy statements 181218621
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183539

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.
Ropinirole implant
Parkinson's disease
CRL issued April 30, 2013. Approved May 26 2016
Probuphine
Opioid dependence

SEC Filings

  1. 8-K - Current report 19600406
  2. 8-K - Current report 19540803
  3. DEF 14A - Other definitive proxy statements 181244461
  4. PRE 14A - Other preliminary proxy statements 181218621
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181183539
  6. 8-K - Current report 181132892
  7. 8-K - Current report 181105670
  8. 8-K - Current report 181086289
  9. 424B3 - Prospectus [Rule 424(b)(3)] 181084607
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181082323